[Treatment of non-resectable stage III non-small cell lung cancer]

The prognosis of locally advanced and non-resectable non-small cell lung cancers (NSCLC) remains poor, despite the therapeutic progress made over the past few years. The best therapeutic strategy is currently the concomitant association of chemotherapy and radiotherapy. Such treatment must be reserved for patients in general state of good health. Oesophagitis is the principle limiting toxicity. The objectives for the years to come are to improve the results and to reduce the toxicity by optimising radiotherapy, using new chemotherapy drugs, and by pinpointing the therapeutic strategy. The sequential association of chemotherapy and radiotherapy still retains its place for the other patients.